Recent advances of NFATc1 in rheumatoid arthritis-related bone destruction: mechanisms and potential therapeutic targets

被引:0
作者
Hao Zheng
Yuexuan Liu
Yasi Deng
Yunzhe Li
Shiqi Liu
Yong Yang
Yun Qiu
Bin Li
Wenbing Sheng
Jinzhi Liu
Caiyun Peng
Wei Wang
Huanghe Yu
机构
[1] Hunan University of Chinese Medicine,TCM and Ethnomedicine Innovation & Development International Laboratory, School of Pharmacy, Innovative Materia Medica Research Institute
来源
Molecular Medicine | / 30卷
关键词
Rheumatoid arthritis; NFATc1; Bone destruction; RANKL/RANK; Osteoclast; Osteoclastogenesis;
D O I
暂无
中图分类号
学科分类号
摘要
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by inflammation of the synovial tissue and joint bone destruction, often leading to significant disability. The main pathological manifestation of joint deformity in RA patients is bone destruction, which occurs due to the differentiation and proliferation of osteoclasts. The transcription factor nuclear factor-activated T cell 1 (NFATc1) plays a crucial role in this process. The regulation of NFATc1 in osteoclast differentiation is influenced by three main factors. Firstly, NFATc1 is activated through the upstream nuclear factor kappa-B ligand (RANKL)/RANK signaling pathway. Secondly, the Ca2+-related co-stimulatory signaling pathway amplifies NFATc1 activity. Finally, negative regulation of NFATc1 occurs through the action of cytokines such as B-cell Lymphoma 6 (Bcl-6), interferon regulatory factor 8 (IRF8), MAF basic leucine zipper transcription factor B (MafB), and LIM homeobox 2 (Lhx2). These three phases collectively govern NFATc1 transcription and subsequently affect the expression of downstream target genes including TRAF6 and NF-κB. Ultimately, this intricate regulatory network mediates osteoclast differentiation, fusion, and the degradation of both organic and inorganic components of the bone matrix. This review provides a comprehensive summary of recent advances in understanding the mechanism of NFATc1 in the context of RA-related bone destruction and discusses potential therapeutic agents that target NFATc1, with the aim of offering valuable insights for future research in the field of RA. To assess their potential as therapeutic agents for RA, we conducted a drug-like analysis of potential drugs with precise structures.
引用
收藏
相关论文
共 575 条
  • [1] Ambros V(2004)The functions of animal microRNAs Nature 431 350-355
  • [2] Amin N(2020)Probiotics and bone disorders: the role of RANKL/RANK/OPG pathway Aging Clin Exp Res 32 363-371
  • [3] Boccardi V(2022)A tetravalent peptide that binds to the RANK-binding region of TRAF6 via a multivalent interaction efficiently inhibits osteoclast differentiation Biochem Biophys Res Commun 636 178-183
  • [4] Taghizadeh M(2023)Inhibition of non-canonical NF-κB signaling suppresses periodontal inflammation and bone loss Front Immunol 14 1179007-264
  • [5] Jafarnejad S(2007)The molecular understanding of osteoclast differentiation Bone 40 251-1269
  • [6] Anzai M(2005)Autoamplification of NFATc1 expression determines its essential role in bone homeostasis J Exp Med 202 1261-66
  • [7] Watanabe-Takahashi M(2019)Circulatory levels of RANKL, OPG, and oxidative stress markers in postmenopausal women with normal or low bone mineral density Biomark Insights 14 1177271919843825-297
  • [8] Kawabata H(2006)Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation Gene 366 58-398
  • [9] Aoki T(2017)Methyl gallate inhibits osteoclast formation and function by suppressing Akt and Btk-PLCγ2-Ca(2+) signaling and prevents lipopolysaccharide-induced bone loss Int J Mol Sci 18 581-2218
  • [10] Hiura F(2004)MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 281-651